|Asset sales and increase in focus|
K John, E Ofek
Journal of financial Economics 37 (1), 105-126, 1995
|Olanzapine versus placebo in the treatment of acute mania|
M Tohen, TM Sanger, SL McElroy, GD Tollefson, KNR Chengappa, ...
American Journal of Psychiatry 156 (5), 702-709, 1999
|Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy|
M Tohen, KNR Chengappa, T Suppes, CA Zarate, JR Calabrese, ...
Archives of general psychiatry 59 (1), 62-69, 2002
|Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone|
M Tohen, KNR Chengappa, T Suppes, RW Baker, CA Zarate, CL Bowden, ...
The British Journal of Psychiatry 184 (4), 337-345, 2004
|The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders|
M Tohen, E Frank, CL Bowden, F Colom, SN Ghaemi, LN Yatham, ...
Bipolar disorders 11 (5), 453-473, 2009
|The expert consensus guideline series. Treatment of behavioral emergencies 2005.|
MH Allen, GW Currier, D Carpenter, RW Ross, JP Docherty
Journal of psychiatric practice 11, 5-108; quiz 110, 2005
|Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness|
R Ganguli, Z Yang, G Shurin, KNR Chengappa, JS Brar, AV Gubbi, ...
Psychiatry research 51 (1), 1-10, 1994
|Emergence of obsessive compulsive symptoms during treatment with clozapine.|
RW Baker, KR Chengappa, JW Baird, S Steingard, MA Christ, ...
The Journal of clinical psychiatry, 1992
|Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder.|
KN Chengappa, T Ebeling, JS Kang, J Levine, H Parepally
The Journal of clinical psychiatry, 1999
|The international society for bipolar disorders–battery for assessment of neurocognition (ISBD‐BANC)|
LN Yatham, IJ Torres, GS Malhi, S Frangou, DC Glahn, CE Bearden, ...
Bipolar disorders 12 (4), 351-363, 2010
|Topiramate as add‐on treatment for patients with bipolar mania|
KN Roy Chengappa, D Rathore, J Levine, R Atzert, L Solai, H Parepally, ...
Bipolar Disorders 1 (1), 42-53, 1999
|Autoimmunity in schizophrenia: a review of recent findings|
R Ganguli, JS Brar, KN Roy Chengappa, ZW Yang, VL Nimgaonkar, ...
Annals of medicine 25 (5), 489-496, 1993
|Identifying and treating cognitive impairment in bipolar disorder|
JF Goldberg, KN Roy Chengappa
Bipolar disorders 11, 123-137, 2009
|The prevalence of the metabolic syndrome in patients with schizoaffective disorder–bipolar subtype|
R Basu, JS Brar, KN Roy Chengappa, V John, H Parepally, S Gershon, ...
Bipolar disorders 6 (4), 314-318, 2004
|Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry|
KR Chengappa, J Levine, S Gershon, DJ Kupfer
Bipolar Disorders 2 (3), 191-195, 2000
|Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry|
KNR Chengappa, DJ Kupfer, E Frank, PR Houck, VJ Grochocinski, ...
American Journal of Psychiatry 160 (9), 1636-1642, 2003
|Inositol as an add‐on treatment for bipolar depression|
KNR Chengappa, J Levine, S Gershon, AG Mallinger, A Hardan, ...
Bipolar disorders 2 (1), 47-55, 2000
|Psychotropic drug prescription patterns among patients with bipolar I disorder|
J Levine, KR Chengappa, JS Brar, S Gershon, E Yablonsky, D Stapf, ...
Bipolar Disorders 2 (2), 120-130, 2000
|Bipolar disorder and the metabolic syndrome|
A Fagiolini, KNR Chengappa, I Soreca, J Chang
CNS drugs 22 (8), 655-669, 2008
|Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review|
KNR Chengappa, L Chalasani, JS Brar, H Parepally, P Houck, J Levine
Clinical therapeutics 24 (10), 1576-1584, 2002